Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Prehospital trauma experience of the Israel defense forces on the Syrian border 2013-2017.

Benov A, Shkolnik I, Glassberg E, Nadler R, Gendler S, Antebi B, Chen J, Fink N, Bader T.

J Trauma Acute Care Surg. 2019 Jul;87(1S Suppl 1):S165-S171. doi: 10.1097/TA.0000000000002217.

PMID:
31246922
2.

Prehospital Trauma Experience of the Israel Defense Forces on the Syrian Border 2013-2017.

Benov A, Shkolnik I, Glassberg E, Nadler R, Gendler S, Antebi B, Chen J, Fink N, Bader T.

J Trauma Acute Care Surg. 2019 Feb 13. doi: 10.1097/TA.0000000000002217. [Epub ahead of print]

PMID:
30768556
3.

Urgent Laparotomy in Patients with Metastatic Colorectal Cancer Presenting as an Acute Abdomen: A Retrospective Analysis.

Gendler S, Shmilovich H, Aranovich D, Nadler R, Kashtan H, Stein M.

Isr Med Assoc J. 2018 Oct;20(10):619-622.

4.

Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Supekar NT, Lakshminarayanan V, Capicciotti CJ, Sirohiwal A, Madsen CS, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ.

Chembiochem. 2018 Jan 18;19(2):121-125. doi: 10.1002/cbic.201700424. Epub 2017 Nov 30.

5.

Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet.

Myers CE, Hoelzinger DB, Truong TN, Chew LA, Myles A, Chaudhuri L, Egan JB, Liu J, Gendler SJ, Cohen PA.

Oncotarget. 2017 Jan 17;8(3):5426-5438. doi: 10.18632/oncotarget.14576.

6.

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA.

Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.

7.

A Flow Cytometry-Based Assay for Procoagulant Platelet Polyphosphate.

Labberton L, Long AT, Gendler SJ, Snozek CL, Stavrou EX, Nickel KF, Maas C, Blankenberg S, Hernandez JS, Renné T.

Cytometry B Clin Cytom. 2018 Mar;94(2):369-373. doi: 10.1002/cyto.b.21492. Epub 2016 Nov 28.

8.

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.

Pathangey LB, Lakshminarayanan V, Suman VJ, Pockaj BA, Mukherjee P, Gendler SJ.

Biomolecules. 2016 Jun 29;6(3). pii: E31. doi: 10.3390/biom6030031.

9.

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Manrique SZ, Dominguez AL, Mirza N, Spencer CD, Bradley JM, Finke JH, Lee JJ, Pease LR, Gendler SJ, Cohen PA.

Oncotarget. 2016 Jul 12;7(28):42919-42942. doi: 10.18632/oncotarget.10190.

10.

Evaluation of a proximity card authentication system for health care settings.

Fontaine J, Zheng K, Van De Ven C, Li H, Hiner J, Mitchell K, Gendler S, Hanauer DA.

Int J Med Inform. 2016 Aug;92:1-7. doi: 10.1016/j.ijmedinf.2016.04.015. Epub 2016 Apr 29.

PMID:
27318066
11.

Design, development and deployment of a Diabetes Research Registry to facilitate recruitment in clinical research.

Tan MH, Bernstein SJ, Gendler S, Hanauer D, Herman WH.

Contemp Clin Trials. 2016 Mar;47:202-8. doi: 10.1016/j.cct.2016.01.010. Epub 2016 Jan 26.

12.

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

Lakshminarayanan V, Supekar NT, Wei J, McCurry DB, Dueck AC, Kosiorek HE, Trivedi PP, Bradley JM, Madsen CS, Pathangey LB, Hoelzinger DB, Wolfert MA, Boons GJ, Cohen PA, Gendler SJ.

PLoS One. 2016 Jan 20;11(1):e0145920. doi: 10.1371/journal.pone.0145920. eCollection 2016.

13.

Muc1 enhances the β-catenin protective pathway during ischemia-reperfusion injury.

Al-Bataineh MM, Kinlough CL, Poland PA, Pastor-Soler NM, Sutton TA, Mang HE, Bastacky SI, Gendler SJ, Madsen CS, Singh S, Monga SP, Hughey RP.

Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F569-79. doi: 10.1152/ajprenal.00520.2015. Epub 2016 Jan 6.

14.

Needle Thoracotomy in Trauma.

Rottenstreich M, Fay S, Gendler S, Klein Y, Arkovitz M, Rottenstreich A.

Mil Med. 2015 Dec;180(12):1211-3. doi: 10.7205/MILMED-D-14-00730. Review.

PMID:
26633663
15.

Intravenous access in the prehospital settings: What can be learned from point-of-injury experience.

Nadler R, Gendler S, Benov A, Shina A, Baruch E, Twig G, Glassberg E.

J Trauma Acute Care Surg. 2015 Aug;79(2):221-6. doi: 10.1097/TA.0000000000000723.

PMID:
26218689
16.

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.

Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ.

Chem Commun (Camb). 2015 Jun 25;51(50):10214-7. doi: 10.1039/c5cc02199e. Epub 2015 May 29.

17.

Muc1 is protective during kidney ischemia-reperfusion injury.

Pastor-Soler NM, Sutton TA, Mang HE, Kinlough CL, Gendler SJ, Madsen CS, Bastacky SI, Ho J, Al-Bataineh MM, Hallows KR, Singh S, Monga SP, Kobayashi H, Haase VH, Hughey RP.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1452-62. doi: 10.1152/ajprenal.00066.2015. Epub 2015 Apr 29.

18.

Reevaluating the selection process for the Israeli Defense Force's paramedic training program.

Lending G, Nadler R, Abramovich A, Gendler S, Peretz A, Dagan D, Gilad D, Glassberg E.

Mil Med. 2015 Mar;180(3 Suppl):158-64. doi: 10.7205/MILMED-D-14-00457.

PMID:
25747647
19.

Eye injury in the Israeli Defense Force: "an ounce of prevention is worth a pound of cure".

Gendler S, Nadler R, Erlich T, Fogel O, Shushan G, Glassberg E.

Injury. 2015 Jul;46(7):1241-4. doi: 10.1016/j.injury.2015.01.035. Epub 2015 Jan 30.

PMID:
25682313
20.

The Israeli Defense Force experience with intraosseous access.

Nadler R, Gendler S, Chen J, Lending G, Abramovitch A, Glassberg E.

Mil Med. 2014 Nov;179(11):1254-7. doi: 10.7205/MILMED-D-14-00013.

PMID:
25373050
21.

Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ.

Cancer Res. 2014 Dec 1;74(23):6845-55. doi: 10.1158/0008-5472.CAN-14-0836. Epub 2014 Oct 8.

22.

Role I trauma experience of the Israeli Defense Forces on the Syrian border.

Benov A, Glassberg E, Nadler R, Gendler S, Erlich T, Bader T, Rasmussen TE, Kreiss Y.

J Trauma Acute Care Surg. 2014 Sep;77(3 Suppl 2):S71-6. doi: 10.1097/TA.0000000000000377. No abstract available.

PMID:
25159365
23.

Tranexamic acid at the point of injury: the Israeli combined civilian and military experience.

Nadler R, Gendler S, Benov A, Strugo R, Abramovich A, Glassberg E.

J Trauma Acute Care Surg. 2014 Sep;77(3 Suppl 2):S146-50. doi: 10.1097/TA.0000000000000325.

PMID:
25159348
24.

Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.

Abdel-Aal AB, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ.

Chembiochem. 2014 Jul 7;15(10):1508-13. doi: 10.1002/cbic.201402077. Epub 2014 May 30.

25.

The value of noninvasive measurement of the compensatory reserve index in monitoring and triage of patients experiencing minimal blood loss.

Nadler R, Convertino VA, Gendler S, Lending G, Lipsky AM, Cardin S, Lowenthal A, Glassberg E.

Shock. 2014 Aug;42(2):93-8. doi: 10.1097/SHK.0000000000000178.

PMID:
24667628
26.

Freeze-dried plasma at the point of injury: from concept to doctrine.

Glassberg E, Nadler R, Gendler S, Abramovich A, Spinella PC, Gerhardt RT, Holcomb JB, Kreiss Y.

Shock. 2013 Dec;40(6):444-50. doi: 10.1097/SHK.0000000000000047. Review. Erratum in: Shock. 2014 Feb;41(2):172.

PMID:
24089000
27.

Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells.

Poh TW, Madsen CS, Gorman JE, Marler RJ, Leighton JA, Cohen PA, Gendler SJ.

Clin Cancer Res. 2013 Sep 15;19(18):5039-52. doi: 10.1158/1078-0432.CCR-13-0278. Epub 2013 Jul 19.

28.

Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA.

Cancer J. 2013 Jul-Aug;19(4):353-64. doi: 10.1097/PPO.0b013e31829da0ae. Review.

29.

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH.

Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Review.

30.

Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Ghosh SK, Uchida M, Yoo B, Ross AW, Gendler SJ, Gong J, Moore A, Medarova Z.

Int J Cancer. 2013 Apr 15;132(8):1860-7. doi: 10.1002/ijc.27872. Epub 2012 Oct 25.

32.

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P.

Cancer Immunol Immunother. 2012 Nov;61(11):2055-65. doi: 10.1007/s00262-012-1264-y. Epub 2012 Apr 28.

33.

MUC1 regulates PDGFA expression during pancreatic cancer progression.

Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, Kidiyoor A, Dalia R, Gendler SJ, Mukherjee P.

Oncogene. 2012 Nov 22;31(47):4935-45. doi: 10.1038/onc.2011.651. Epub 2012 Jan 23.

34.

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):261-6. doi: 10.1073/pnas.1115166109. Epub 2011 Dec 14.

35.

Core-glycosylated mucin-like repeats from MUC1 are an apical targeting signal.

Kinlough CL, Poland PA, Gendler SJ, Mattila PE, Mo D, Weisz OA, Hughey RP.

J Biol Chem. 2011 Nov 11;286(45):39072-81. doi: 10.1074/jbc.M111.289504. Epub 2011 Sep 20.

36.

Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice.

Pinkhasov J, Alvarez ML, Rigano MM, Piensook K, Larios D, Pabst M, Grass J, Mukherjee P, Gendler SJ, Walmsley AM, Mason HS.

Plant Biotechnol J. 2011 Dec;9(9):991-1001. doi: 10.1111/j.1467-7652.2011.00614.x. Epub 2011 Jul 11.

37.

Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.

Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, Hwang SI, Lee YY, Gendler SJ, Mukherjee P.

Cancer Res. 2011 Jul 1;71(13):4432-42. doi: 10.1158/0008-5472.CAN-10-4439. Epub 2011 May 10.

38.

Nocturic episodes in patients with benign prostatic enlargement may suggest the presence of obstructive sleep apnea.

Tandeter H, Gendler S, Dreiher J, Tarasiuk A.

J Am Board Fam Med. 2011 Mar-Apr;24(2):146-51. doi: 10.3122/jabfm.2011.02.100110.

39.

Importance and regulation of the colonic mucus barrier in a mouse model of colitis.

Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, Roos S, Holm L, Phillipson M.

Am J Physiol Gastrointest Liver Physiol. 2011 Feb;300(2):G327-33. doi: 10.1152/ajpgi.00422.2010. Epub 2010 Nov 25.

40.

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.

Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, Gendler SJ, Mukherjee P.

Oncogene. 2011 Mar 24;30(12):1449-59. doi: 10.1038/onc.2010.526. Epub 2010 Nov 22.

41.

Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model.

Pinkhasov J, Alvarez ML, Pathangey LB, Tinder TL, Mason HS, Walmsley AM, Gendler SJ, Mukherjee P.

Cancer Immunol Immunother. 2010 Dec;59(12):1801-11. doi: 10.1007/s00262-010-0906-1. Epub 2010 Sep 8.

42.

Decreasing trends in HTLV-1/2 but stable HIV-1 infection among replacement donors in Argentina.

Berini CA, Gendler SA, Pascuccio S, Eirin ME, McFarland W, Page K, Carnevali L, Murphy E, Biglione MM.

J Med Virol. 2010 May;82(5):873-7. doi: 10.1002/jmv.21728.

PMID:
20336721
43.

Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.

Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ, Calderwood SK, Gong J.

Oncogene. 2009 Dec 3;28(48):4225-36. doi: 10.1038/onc.2009.268. Epub 2009 Sep 7.

PMID:
19734944
44.

Expression of human MUC1 during early pregnancy in the human MUC1 transgenic mouse model.

Dharmaraj N, Gendler SJ, Carson DD.

Biol Reprod. 2009 Dec;81(6):1182-8. doi: 10.1095/biolreprod.109.079418. Epub 2009 Aug 14.

45.

Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow.

Poh TW, Bradley JM, Mukherjee P, Gendler SJ.

Cancer Res. 2009 Apr 15;69(8):3554-62. doi: 10.1158/0008-5472.CAN-08-3806. Epub 2009 Apr 7.

46.

Small bowel obstruction caused by intramural hemorrhage secondary to anticoagulant therapy.

Cheng J, Vemula N, Gendler S.

Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):342-4.

PMID:
19198584
47.

The gastric mucus layers: constituents and regulation of accumulation.

Phillipson M, Johansson ME, Henriksnäs J, Petersson J, Gendler SJ, Sandler S, Persson AE, Hansson GC, Holm L.

Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G806-12. doi: 10.1152/ajpgi.90252.2008. Epub 2008 Aug 21.

48.

Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.

Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA.

J Biol Chem. 2008 Oct 3;283(40):26985-95. doi: 10.1074/jbc.M805036200. Epub 2008 Jul 14.

49.

[Seroconversion of hepatitis C in blood donors].

Pascuccio MS, Gendler SA, Carnevali L, Fuse V.

Medicina (B Aires). 2007;67(6 Pt 2):771-2. Spanish. No abstract available.

PMID:
18422076
50.

Titanium and zirconium complexes of robust salophan ligands. Coordination chemistry and olefin polymerization catalysis.

Gendler S, Zelikoff AL, Kopilov J, Goldberg I, Kol M.

J Am Chem Soc. 2008 Feb 20;130(7):2144-5. doi: 10.1021/ja077998j. Epub 2008 Jan 25. No abstract available.

PMID:
18217760

Supplemental Content

Loading ...
Support Center